Human IL-12 Protein, premium grade
分子别名(Synonym)
IL12,p70,Interleukin-12
表达区间及表达系统(Source)
Human IL-12 Protein, premium grade (IL2-H5210) is expressed from human 293 cells (HEK293). It contains AA Ile 23 - Ser 328 & Arg 23 - Ser 219 (Accession # P29460-1 & P29459-1).
Predicted N-terminus: Ile 23
该产品在我们严格的质量控制体系下生产,涵盖包括无菌和内毒素检测在内的全面测试方案。其产品性能经过严谨验证,并针对细胞培养用途及临床前阶段的其他应用进行了兼容性测试。
GMP-L12H23是本产品IL2-H5210的GMP级别版本。两种蛋白质表现出完全一致的性能特征,可确保终端用户从早期临床前研究到后续临床阶段实现无缝转换。
蛋白结构(Molecular Characterization)
This protein carries no "tag".
The protein has a calculated MW of 58.9 kDa. The protein migrates as 76 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method / rFC method.
宿主蛋白残留(Host Cell Protein)
<0.5 ng/µg of protein tested by ELISA.
宿主核酸残留(Host Cell DNA)
<0.02 ng/μg of protein tested by qPCR.
无菌(Sterility)
Negative
支原体(Mycoplasma)
Negative.
纯度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.



背景介绍
白细胞介素12(IL-12,又称p70)是一种由树突状细胞、巨噬细胞和人B淋巴母细胞(NC-37株)在抗原刺激下天然产生的白细胞介素。该细胞因子为异二聚体结构,由IL-12A(p35)和IL-12B(p40)两个亚基组成。IL-12参与初始T细胞向Th1细胞的分化过程,被誉为T细胞刺激因子,能促进T细胞生长并增强其功能。它可刺激T细胞和自然杀伤(NK)细胞产生γ-干扰素(IFN-γ)和α-肿瘤坏死因子(TNF-α),并减弱IL-4对IFN-γ的抑制效应。IL-12在自然杀伤细胞和T淋巴细胞的免疫活性中发挥重要作用,同时具有抗血管生成活性,即能够阻断新血管的形成。
关键字: IL-12;IL-12蛋白;IL-12重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。